FDA will rapidly approve DCVax as our data are far more robust than toxic yet approved CAR-T. NWBO applied to UK because first they're very familiar with DCVax via the Specials Program. If US had similar innovations more than a decade ago we could have applied here before the UK.
Under Orbis MHRA can refer our application to all other regulatory authorities (RAs) without need for NWBO to submit separate applications to other RAs.
The notion that FDA prefers mRNA over DCVax isn't true. mRNA simply has greater awareness due to Covid-19. We have superior technology by far. It will be approved without issue.